It is becoming a familiar scene, you board the plane and hear the crew announce: “We have a passenger with a severe nut allergy today. We won’t be selling any products with nuts or peanuts, and we ask that you do not consume any while you are onboard.”
While some passengers grumble about being deprived of their nutty snacks, this announcement can make an already tricky situation marginally easier for people with severe allergies to peanuts and tree nuts.
The problem is that there is no blanket policy on what airlines do to help travellers with these allergies. Each has its own way of dealing with the issue. In fact, just today easyJet announced it would soon be serving zero nut products on board (including “reformulating” baklava so it doesn’t contain nuts).
Allergy Therapeutics (LON:AGY) is an international commercial biotechnology group focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.